Single-Use Bioreactors Market To Generate $13,595.9 Million Revenue by 2030
- Published: June 2023
Growing at a CAGR of 18.8% between 2022 and 2030, the single-use bioreactors market value is expected to reach USD 13,595.9 million by 2030. The growth can be accredited to the rising prevalence of infectious and non-infectious diseases, technological advancements in this field, surging research and development activities, and the increasing number of collaborations among companies.
Over the years, significant growth in both infectious and non-infectious diseases like influenza, diabetes, and others has been observed. In order to provide easy, fast, and flexible deployment, a number of firms begin to focus on quick and time-saving flexible approaches to manufacture biopharmaceutics as rapidly as possible without compromising the quality of the same. Thus, biopharmaceutical firms are adopting single-use bioreactors, as they offer many advantages over traditional bioreactors, such as providing complete validation and qualification process, lowering the risk of cross-contamination, and refining safety of the whole process in the production of potent biopharmaceuticals.
Additionally, many major companies are increasingly launching such single-use systems, expanding their facilities, and collaborating with other players, to gain a competitive edge in the market. For instance, in February 2021, a Hong Kong-listed company, WuXi Biologics announced that its manufacturing facility located in China launched GMP operations having a capacity of thirty-six thousand liters utilizing nine four-thousand-liter single-use bioreactors. Moreover, in January 2021, a German-based firm Sartorius AG collaborated with RoosterBio Inc., to enhance the production of regenerative medicines. Therefore, such initiatives are projected to significantly boost the demand for such bioreactors in the upcoming years.
Research & Development Category Dominates the Market
On the basis of application, the research & development category accounted for the largest revenue share, of 50%, in 2022. This is attributable to the surging use of single-use bioreactors for a number of research and development activities. A study indicated that a large number of pharmaceutical firms, i.e., approximately 70%, use single-use systems in the upstream research and development process.
Whereas, the bioproduction category is projected to display significant growth during the forecast period. This can be because of the growing prevalence of viral infections in recent years and the surging advancements in the design of bioreactors and advancements in the field of gene as well as cell therapies.
CROs & CMOs Category Leads the Industry
On the basis of end user, the CRO & CMO category leads the market share. This is because contract manufacturing organizations (CMOs) deal with a wide variety of products in comparison to innovator firms, which deal with lesser products and have more time for optimization during the downstream bioprocessing. Thus, CMOs prefer to use single-use bioreactors, as they offer flexibility, quick changeover time, and rapid turnaround time.
Additionally, such systems significantly decrease the capital investments and operating costs of CMOs by saving on campaign and facility costs. Moreover, rapid turnaround times between client projects and the process runs enhance their efficiency, leading to reduced costs. Such cost reduction can lead to significant savings that can be passed on to clients and eventually to patients. This can ultimately increase an organization’s profit as well.
Whereas, pharmaceutical & biotechnology companies are projected to generate high demand for single-use bioreactors in the coming years. This can be ascribed to the rising number of product advancements, product launches, and collaborations among top players.
Asia-Pacific Market To Register Fastest Growth
Geographically, the APAC market is expected to display the highest growth rate during the forecast period. This can be because of the presence of a significant number of people suffering from chronic and infectious diseases, the rising incidence of contagious diseases, and the presence of government policies favoring research and development activities in the region.
Some key players in the market are Sartorius AG, Thermo Fisher Scientific Inc., Getinge AB, Merck KGaA, Eppendorf SE, PBS Biotech Inc., Distek Inc., ABEC Inc., G&G Technologies Inc., and Solida Biotech GmBH.